Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04836273
Other study ID # CKN-DASI120-RYGB
Secondary ID 2020-005241-16
Status Completed
Phase Phase 2
First received
Last updated
Start date August 20, 2021
Est. completion date December 15, 2022

Study information

Verified date February 2023
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and out-patient part. The primary aim of the study is to compare the effects of self-administered 120 µg dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in hypoglycaemia in RYGB-operated individuals in an out-patient setting.


Description:

Study design: Before inclusion in the study, the participants will complete a screening visit and a blinded 14-day continuous glucose monitoring (CGM) run-in period to ascertain a regular occurrence of postprandial hypoglycaemia (IG <3.9 mmol/l, ≥3 times/week). After enrolment in the study, the participants will wear a CGM for the entirety of the study period (apart from the four weeks before the follow-up visit). Prior to the first mixed meal test (MMT) during the in-patient part, the subjects will be randomised into one of four double-blinded treatment sequences consisting of an in-patient part (two MMTs) follow by a nine weeks out-patient part (two times four weeks per out-patient part with an interposed washout period of one week) and ended with a follow-up visit four weeks after out-patient part completion. During the in-patient part, the participants will undergo two separate MMTs, with a minimum of 7 days in-between, accompanied by one of the following double-blind, randomised, placebo-controlled crossover interventions: 1. Subcutaneous placebo self-administration 2. Subcutaneous 120 µg dasiglucagon self-administration The out-patient part is divided into two double-blinded, randomised, placebo-controlled crossover out-patient parts with of the following interventions: 1. Subcutaneous placebo self-administration 2. Subcutaneous 120 µg dasiglucagon self-administration


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 15, 2022
Est. primary completion date May 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Documented postprandial hypoglycaemia (IG <3.9 mmol/l, =3 times/week) assessed by 14-days of blinded CGM recording - Haemoglobin levels for women >7.3 mmol/l and for men >8.3 mmol/l - Ferritin >10 µg/l - Cobalamin >150 pmol/l - Fasting plasma glucose concentration within the range of 4.0-6.0 mmol/l - Normal electrocardiogram (ECG) - Negative urine human chorionic gonadotropin (hCG) (for fertile women) Exclusion Criteria: - Treatment with medication(s) affecting insulin secretion, glucose metabolism or any antidiabetic drugs - Treatment with antipsychotics - Current participation in another clinical trial with administration of investigational drug - Previous exposure to dasiglucagon (also known as ZP4207) within the last 30 days prior screening - History of liver disease that is expected to interfere with the anti-hypoglycaemic action of glucagon (e.g. liver failure or cirrhosis) - Pregnancy - Breastfeeding - Major surgery within 30 days before screening - Alcohol abuse (per investigator assessment) - Any factors that, in the opinion of the site principal investigator or clinical protocol chair, would interfere with the safe completion of the study, including medical conditions that may require hospitalization during the trial - History of pheochromocytoma or insulinoma - History of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients - Known or suspected allergies to glucagon or related products

Study Design


Intervention

Drug:
Dasiglucagon
Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Device:
HyoPen
multi-dose reusable pen injector
Drug:
Placebo
Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.

Locations

Country Name City State
Denmark Center for Clinical Metabolic Research, Herlev-Gentofte Hospital Hellerup

Sponsors (2)

Lead Sponsor Collaborator
Filip Krag Knop Zealand Pharma

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time spent in hypoglycaemia (IG < 3.9 mmol) The primary endpoint is the percentage of time in hypoglycaemia (IG <3.9 mmol/l) assessed by CGM during the out-patient part. During the four weeks of placebo and dasiglucagon treatment.
Secondary Time (percent or minutes) spent in serious hypoglycaemia (IG <3.0 mmol/l) During the four weeks of placebo and dasiglucagon treatment.
Secondary Frequency of hypoglycaemic events (IG <3.9 mmol/l and <3.0 mmol/l, respectively) During the four weeks of placebo and dasiglucagon treatment.
Secondary Glycaemic time in range defined as: 1) hypoglycaemia (<3.9 mmol/l), 2) normoglycaemia (3.9-10.0 mmol/l), and 3) hyperglycaemia (>10.0 mmol/l) During the four weeks of placebo and dasiglucagon treatment.
Secondary Frequency of hyperglycaemic events (IG >7.8 mmol/l and >10.0 mmol/l, respectively) During the four weeks of placebo and dasiglucagon treatment.
Secondary Glycaemic variability assessed as coefficient of variance (CV) During the four weeks of placebo and dasiglucagon treatment.
Secondary Glycaemic variability assessed as standard deviation (SD) During the four weeks of placebo and dasiglucagon treatment.
Secondary Recovery of BG 15 minutes after trial drug administration (as measured by finger prick (BG >3.9 mmol/l)) During the four weeks of placebo and dasiglucagon treatment.
Secondary Change in QoL as assessed by the World Health Organization's quality of life assessment (WHOQOL-BREF) likert scale, zero (very poor) to five (very good) During the four weeks of placebo and dasiglucagon treatment.
Secondary Change in hypoglycaemic symptoms will be evaluated by Edinburgh Hypoglycaemia Symptom Scale (EHSS) likert scale, zero (not a all) to seven (a lot) During the four weeks of placebo and dasiglucagon treatment.
Secondary Change in fear of hypoglycaemia as assessed by Hypoglycaemia Fear Scale (HFS-II) likert scale, zero (never) to four (always) During the four weeks of placebo and dasiglucagon treatment.
Secondary Change in administration frequency (as measured by percentage) During the four weeks of placebo and dasiglucagon treatment.
Secondary Nadir plasma glucose as assessed both as 1) absolute lowest value, and 2) a mean of three consecutive glucose measurements during the 240-minute MMT Nadir plasma glucose after the postprandial peak during the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Recovery of BG 15 minutes after administration (as measured by finger prick (BG >3.9 mmol/l)) After the postprandial peak during the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Time spent in level 1 and level 2 hypoglycaemia (<3.9 and <3.0 mmol/l, respectively) from study drug administration until 240 minutes After the postprandial peak during the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Glycaemic rescue intervention due to critically low plasma glucose concentration (<1.8 mmol/l) During the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Time spent in hyperglycaemia (>7.8 mmol/l) from study drug administration until 240 minutes During the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Peak plasma glucose concentration after study drug administration During the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Counter-regulatory hormonal response Measured as area under the curve (AUC) and / or incremental (iAUC) as appropriate, peak values and values at nadir plasma glucose concentration during the MMT in the in-patient part. glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), glucose-dependent insulinotropic polypeptide (GIP) Two hundred forty minutes of mixed meal test
Secondary Changes in blood pressure During the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Changes in heart rate During the MMT in the in-patient part Two hundred forty minutes of mixed meal test
Secondary Frequency and severity of adverse events (AE)s and serious adverse events (SAE)s from signed consent form to end of study (visit 4 / follow-up visit) Safety endpoint Through study completion which is an average of 16 weeks
Secondary Frequency and severity of adverse events (AE)s and serious adverse events (SAE)s during the in-patient part MMTs Safety endpoint During the in-patient part (MMTs) 0-240 minutes / Two hundred forty minutes of mixed meal test
Secondary Percentage (%) of participants with treatment-induced or treatment-boosted anti-dasiglucagon antibodies who did not have anti-dasiglucagon antibodies at baseline Safety endpoint Through study completion which is an average of 16 weeks
Secondary Device failures/ malfunctions occurring during the trial. Device endpoint Through study completion which is an average of 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT03984370 - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass Phase 2
Completed NCT03200782 - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study N/A
Recruiting NCT05036317 - Empagliflozin for the Treatment of Postprandial Hypoglycemia Phase 3
Active, not recruiting NCT05174507 - Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes Phase 2
Completed NCT04330196 - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance. N/A
Recruiting NCT04720859 - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) N/A
Completed NCT05676385 - Glucose Response to a Formula for Patients at Risk of Hypoglycaemia N/A
Completed NCT05513404 - The Scottish Fruit Study N/A
Completed NCT01162499 - Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia N/A
Recruiting NCT05401578 - Canakinumab for the Treatment of Postprandial Hypoglycemia Phase 3